<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>23(10)</volume><submitter>Koren MA</submitter><funding>NIAID NIH HHS</funding><journal>The Lancet. Infectious diseases</journal><pagination>1175-1185</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10877583</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.</pubmed_title><pmcid>PMC10877583</pmcid><funding_grant_id>R01 AI155983</funding_grant_id><pubmed_authors>Valencia-Ruiz A</pubmed_authors><pubmed_authors>Curley JM</pubmed_authors><pubmed_authors>Donofrio G</pubmed_authors><pubmed_authors>Gromowski GD</pubmed_authors><pubmed_authors>Costanzo M</pubmed_authors><pubmed_authors>Lee C</pubmed_authors><pubmed_authors>Dussupt V</pubmed_authors><pubmed_authors>Jarman RG</pubmed_authors><pubmed_authors>De La Barrera R</pubmed_authors><pubmed_authors>Thomas SJ</pubmed_authors><pubmed_authors>Amare MF</pubmed_authors><pubmed_authors>Adedeji O</pubmed_authors><pubmed_authors>Mebrahtu T</pubmed_authors><pubmed_authors>Darden J</pubmed_authors><pubmed_authors>Mills KT</pubmed_authors><pubmed_authors>Crowell TA</pubmed_authors><pubmed_authors>Hamer MJ</pubmed_authors><pubmed_authors>Koren MA</pubmed_authors><pubmed_authors>Sondergaard EL</pubmed_authors><pubmed_authors>Copeland NK</pubmed_authors><pubmed_authors>Peel S</pubmed_authors><pubmed_authors>Keiser PB</pubmed_authors><pubmed_authors>Modjarrad K</pubmed_authors><pubmed_authors>Robb ML</pubmed_authors><pubmed_authors>Krebs SJ</pubmed_authors><pubmed_authors>Hutter JN</pubmed_authors><pubmed_authors>Michael NL</pubmed_authors><pubmed_authors>Lin L</pubmed_authors><pubmed_authors>Eckels KH</pubmed_authors></additional><is_claimable>false</is_claimable><name>Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trial.</name><description/><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Oct</publication><modification>2026-05-29T11:40:37.519Z</modification><creation>2025-02-18T23:23:47.494Z</creation></dates><accession>S-EPMC10877583</accession><cross_references><pubmed>37390836</pubmed><doi>10.1016/S1473-3099(23)00192-5</doi><doi>10.1016/s1473-3099(23)00192-5</doi></cross_references></HashMap>